Life Sciences IPO Readiness: 4 Areas To Assess Before Filing

An IPO readiness assessment that includes these four areas helps companies reduce delays, strengthen governance, and improve preparedness.

Market conditions often influence when companies go public, but life sciences organizations also should assess their readiness when planning for a successful IPO.

The race to meet public-company expectations can uncover unexpected delays because operational issues frequently emerge, even well before companies enter the filing process. Accounting, governance, and financial reporting gaps often remain hidden until management begins preparing the company for public markets. Strong science and favorable market conditions still matter, but they do not eliminate the need for public-company infrastructure. That’s why it’s important for life sciences companies to start IPO preparation early, often at least 12 to 18 months before an anticipated transaction.

One of the best ways to start preparing is through an IPO readiness assessment. Management teams can focus on four key areas to help mitigate issues and delays.

Focus area 1: Operational infrastructure

A favorable IPO window in the markets creates opportunity, but life sciences organizations still need the operational infrastructure to take advantage of that timing. Public companies face high expectations for financial reporting, governance, internal controls, and regulatory compliance, which means investors and regulators expect timely reporting, consistent processes, and well-documented financial information.

Clinical progress alone does not satisfy those expectations, and that can surprise management teams. Life sciences companies often devote substantial attention to clinical progress, fundraising, and commercialization strategy, but preparing for life as a public company requires an equally deliberate investment in finance and accounting functions. Meeting these expectations requires finance and accounting teams to strengthen relevant business and operational processes, evaluate controls over financial reporting, and identify and track quantifiable developments that might inform accounting estimates. A life sciences company might have achieved key clinical milestones, completed multiple financing rounds, and undergone independent audits of its private-company financial statements yet still require significant work before it is ready for the public markets.

Life sciences organizations that start preparing for an IPO early have time to evaluate existing processes, strengthen weak areas, and build sustainable reporting practices before transaction timelines begin to narrow.

Focus area 2: Beyond a private-company audit

One misconception often appears during IPO preparation: Completion of private-company financial statement audits means the organization is ready to transition to public-company reporting. That assumption often leads to unexpected delays. The audits of financial statements included in an IPO registration statement must be performed in accordance with Public Company Accounting Oversight Board (PCAOB) standards, which might involve changes in materiality considerations and the audit approach, including changes to the nature or extent of audit procedures.

Additionally, financial statements included in an IPO registration statement must meet Securities and Exchange Commission (SEC) presentation and disclosure requirements as well as U.S. GAAP requirements applicable to public companies, which might require additional disclosures and a different level of precision and detail than private-company financial reporting. Many life sciences companies discover those differences only after IPO preparation is underway, when management already is balancing registration statement drafting, due diligence, and day-to-day operations.

Focus area 3: Accounting issues

As companies prepare financial statements to meet U.S. GAAP and SEC reporting requirements applicable to public companies, they often identify accounting and reporting matters that require additional analysis and documentation. Common examples include:

• Technical accounting positions that require additional support
• Revenue recognition analyses that need stronger documentation
• Clinical trial and contract research organization accruals and other significant estimates
• Stock-based compensation and accounting for complex equity or financing instruments and other significant transactions completed before the offering
• Private-company accounting alternatives that must be reversed
• Equity classification changes required under public-company reporting rules
• Expanded financial statement disclosures

Each issue generally can be resolved on its own, but challenges can arise when several appear at once and must be addressed alongside other transaction-related workstreams and deadlines.

The accounting work also tends to reveal larger organizational issues:

• Finance processes might need to mature.
• Governance structures might require refinement.
• Documentation practices that worked well for a private company often need to become more formal before an IPO can proceed. Those discoveries are far easier to manage before the transaction is on the clock.

Focus area 4: Adequate lead time

Life sciences companies cannot control the capital markets, but they can control how prepared they are when market conditions are favorable. An IPO readiness assessment allows management to evaluate a range of areas, such as financial reporting, governance, internal capabilities, and technical accounting before the transaction becomes the organization’s primary focus. Starting at least 12 to 18 months before a potential offering provides time to address deficiencies methodically instead of through last-minute remediation. Preparation is far less disruptive and far less costly than remediation during registration statement drafting or under the pressure of an offering timeline.

The preparatory work also pays dividends after the offering. Life sciences companies with stronger finance organizations, established reporting processes, and mature governance practices enter the public markets with a foundation built for ongoing SEC reporting rather than simply completing the IPO.

For life sciences companies considering an IPO within the next two years, readiness deserves the same attention as market conditions. Early preparation helps reduce disruption, supports a more efficient transaction, and positions the organization for the ongoing demands of operating as a public company.